Need for surgery in patients with ulcerative colitis in the era of biologic therapy
Journal of Crohn's and Colitis(2022)
摘要
Abstract Background The aim of the present study is to evaluate the impact of anti-TNF drugs on the need for surgery among patients with ulcerative colitis (UC). Secondary objectives: to compare needs for medical treatment before surgery, indications for surgery and surgery-free survival. Methods Observational, retrospective and single-center study that includes patients with UC who have required surgery for inflammatory bowel disease (IBD). Two cohorts of UC patients were analyzed: cohort-1 (pre-antiTNF) with a diagnosis of UC between 1995–2000, and cohort-2 (post-antiTNF) diagnosed after the approval of anti-TNF between 2010–2015. Patients were followed up to the event (surgery) or at least five years since UC diagnosis. Demographic variables related to UC and surgery were collected. Kaplan-Meier curves were performed to compare the surgery-free survival in both cohorts. The ENEIDA registry was used to identify the patients. Results A total of 32 patients underwent surgery were included (18 in cohort 1 and 14 in cohort 2). The mean age at UC diagnosis was significantly lower in cohort 1 (31.3 vs 46.4 years, p=0.015), and the proportion of smoking patients was higher in cohort 1 (27.8% vs 0%, p=0.053). There were no differences between the two cohorts in the extent of UC and extraintestinal manifestations. Surgery rates were 3.7% in cohort-1 and 4.7% in cohort-2. Overall, there were no differences in colectomy rates in both cohorts (Figure 1). However, the median time from UC diagnosis to surgery was significantly longer in cohort-2 (21 vs. 1 months, p<0.05) (Figure 2). Regarding the surgery timing, the proportion of urgent surgery was higher in cohort-1 (61% vs 43%, ns); while in cohort-2, scheduled surgery predominated (50% vs 18%, ns). In the subgroup of patients who underwent scheduled surgery, the surgery free time was significantly longer in cohort-2: 67 vs 12 months (p=0.01) (Figure 3). Regarding surgical indications, cohort-1: 78% acute severe colitis or acute complications and 22% refractory to medical therapy; cohort-2: 43% Acute Severe Colitis/complications. A high proportion of patients in both cohorts required ostomy (temporary or definitive). Pre-surgery medical treatment needs cohort-1 vs cohort-2: steroids (100% vs 71%, p=0.028), immunosuppressants (5.6% vs 57%, p=0.002). Figure 1. Surgery -free survival at 5-years follow-up. Figure 2. Kaplan-Meier curves of time from UC diagnosis to surgery. Figure 3. Kaplan-Meier curves of time until scheduled surgery. Conclusion Surgery rates in UC patients remain stable in the post-antiTNF era. However, the arrival of antiTNF drugs allows a longer surgery-free survival, lower preoperative steroids requirements and less need for urgent surgery.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要